Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection

Abstract

Background: The association between gastric acid suppression, particularly through the use of proton pump inhibitors (PPIs), and recurrent Clostridium difficile infection (CDI) has garnered significant attention in the medical literature over the past decade. The body of research surrounding this topic reveals a complex interplay between acid suppression therapies and the risk of CDI, with various studies contributing critical insights that enhance our understanding of this public health concern. Literature Review: Research conducted by (Jaynes & B. Kumar, 2018) and (Kachrimanidou & Tsintarakis, 2020) further elucidates the impact of PPIs on gut microbiota, revealing that long-term use can diminish microbial diversity, thereby reducing colonization resistance against C. difficile and increasing susceptibility to recurrent infections. Conversely, some articles, such as the one by (Novack et al., 2014), challenge the direct causality between PPI use and CDI risk, suggesting that observational studies may be biased and that confounding factors, particularly antibiotic use, should not be overlooked in this context. The implications of PPI use extend beyond infection risk; studies like that of (Stuart Bradley et al., 2019) indicate that PPI exposure may also influence mortality rates among elderly patients post-CDI treatment, further complicating the clinical landscape. Conclusion : In conclusion, the literature collectively underscores the critical need for healthcare providers to carefully weigh the benefits of PPI therapy against the potential risks of CDI, particularly in populations at heightened risk. The association between gastric acid suppression and CDI is complex, necessitating further research to elucidate the underlying mechanisms and to develop informed prescribing practices.